PMVP PMV Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1699382 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-7.0%
TTM EPS YoY1.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-99.4%
ROA-72.2%
ROIC (approx.)-100.2%
Asset turnover—
Leverage & solvency
Liabilities / assets48.7%
Debt / equity0.00x
Current ratio9.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $69.88M | $58.53M |
| SG&A expense | $16.33M | $26.92M |
| Operating income | -$86.21M | -$85.45M |
| Pretax income | -$79.91M | -$74.81M |
| Income tax | -$2.17M | -$16.10M |
| Net income | -$77.74M | -$58.71M |
| EBITDA | -$86.07M | -$84.30M |
| EPS (basic) | -1.48 | -1.14 |
| EPS (diluted) | -1.48 | -1.14 |
| Weighted avg. shares (diluted) | 52.54M | 51.58M |
| Banking | ||
| Net interest income | $6.34M | $10.65M |
| Balance sheet | ||
| Cash & equivalents | $37.98M | $40.88M |
| Short-term investments | $74.96M | $128.58M |
| Current assets | $115.23M | $175.66M |
| PP&E, net | $237,000 | $409,000 |
| Total assets | $116.56M | $191.29M |
| Current liabilities | $11.41M | $14.37M |
| Total liabilities | $11.85M | $15.21M |
| Shareholders' equity | $104.71M | $176.08M |
| Shares outstanding | 53.33M | 51.94M |
| Cash flow statement | ||
| Operating cash flow | -$73.58M | -$51.28M |
| Capital expenditure | $29,000 | $655,000 |
| Free cash flow | -$73.61M | -$51.94M |
| Investing cash flow | $70.17M | $53.35M |
| Financing cash flow | $505,000 | $313,000 |
| Depreciation & amortization | $133,000 | $1.14M |
| Stock-based compensation | $5.92M | $8.87M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.